No FDA Compromise On Veregen Specifications In First Botanical NDA Review
This article was originally published in Pharmaceutical Approvals Monthly
The first botanical NDA, MediGene’s Veregen (kunecatechins), illuminated gaps in the emerging regulatory framework for plant-derived prescription drugs, FDA review documents indicate.
You may also be interested in...
Amryt’s birch bark extract oleogel-S10 for Epidermolysis Bullosa patients might become only the third botanical drug to clear the FDA.
Salix’ botanical product Fulyzaq tested the limits of the conventional small molecule chemistry approach to ensuring the identity of drug substance. After a regulatory briefing with CDER Director Woodcock, the botanicals and CMC review teams agreed on a bioassay to bridge the gap in their regulatory perspectives.
FDA's final approval tally of new molecular entities in 2006 is almost a 25-year low, despite early signs that the agency was on pace to best last year's final count of NME approvals